MYC and cancer: This dysregulation may represent both an adaptive response to the high biosynthetic demands of rapidly proliferating cancer cells and, in some contexts, a metabolic vulnerability that promotes oncogenic signaling via c-Myc, mTORC1, and redox control networks.